The Company
Research & Development
Product Pipeline
Technology Platforms
Superhumanisation™
Synhumanisation®
Evogene™
Inflammation Franchise
ART621
PMX
Cancer Franchise
ART010
ART150
ART104
ART101
ART140
ART160
Clinical Trials Background
Glossary
Intellectual Property
Investor Relations Centre
News & Media
Business Development
General Links
Careers
Contact Us
HOME
ART101
ART101 is a monoclonal antibody that rapidly kills tumour cells over-expressing a specific Lewis
y/b
antigen associated particularly with intestinal tumours. ART101 is in early stage development for colorectal cancer.